The demand graph of the global chronic kidney disease (CKD) drugs market is treading along a lucrative track. The importance of healthy kidneys for the human body cannot be underestimated. The kidneys are not only an important body organ, but also a part of the larger human anatomy responsible for several functions. The functions of the kidney in the human body span into several areas of nephrology. Furthermore, kidney disorders can damage several functionalities in the human body. It is safe to assert that several functions of the human body rely on healthy subsistence of the kidneys. It is a matter of attention that kidney failure cannot be reversed, and only a healthy kidney can help restore the corresponding functionalities. Therefore, the total volume of revenues within the global chronic kidney disease (CKD) drugs market is set to rise.

In this report preview, Transparency Market Research furnishes several important trends and propensities that have aided the expansion of the global chronic kidney disease (CKD) drugs market. Furthermore, constant dialysis also necessitates the use of important drugs that can complement the process. Over the course of the next decade, the global chronic kidney disease (CKD) drugs market is set to attract fresh investments. The focus of the healthcare industry on collaborating with drug development entities has given an impetus to market maturity.

chronic kidney disease drugs market

Severity of Symptoms of CKD

Several symptomatic tendencies are related to the occurrence of chronic kidney disorders. Kidneys play an important role in ensuring timely and healthy urination, and this functionality is disrupted in the case of diseases kidneys. Furthermore, kidney disorders can disturb the sleeping and eating routines of the masses, creating new opportunities for growth across the global chronic kidney disease (CKD) drugs market. Several new drugs to treat kidney disorders have been developed in recent times. This trend shall cause an uptick in demand across the chronic kidney disease (CKD) drugs market.

Rising Geriatric Population to Drive Demand

A large geriatric population suffers from kidney disorders that can cripple them of basic functioning. Regular dialysis helps these individuals in experiencing temporary relief from kidney and urinal pain. However, it is important to develop drugs that can support patients who do not resort timely dialysis. The occurrence of chronic kidney disease (CKD) in youngsters can be a source of pain and discomfort. Therefore, the use of chronic kidney disease (CKD) drugs in this population group shall rise in the years to follow. Several medical research institutes have recommended new drug formulae for the treatment of kidney disorders.

Importance of Timely Treatment

Chronic kidney diseases can be a source of several other problems such as puffiness of eyes. Inconsistent sleeping patterns, urinary pain, skin irritation, and swollen ankles. Therefore, it is imperative for medical practitioners to ensure kidney disorders are treated and controlled at the earliest. The humongous importance of chronic kidney disease (CKD) drugs post dialysis has given a thrust to market growth. The next decade would be crucial in deciding the growth direction of the global chronic kidney disease (CKD) drugs market.

Growth of North America Market

On the basis of geography, several new regions have acquired fruition in the chronic kidney disease (CKD) drugs market. The healthcare sector of the US has acquired fresh revenues in recent times, mainly due to the inflow of fresh investments. The focus on treating kidney disorders, especially for the geriatric population, has played a vital role in market growth and maturity.

Some of the notable players who have made a mark in the global chronic kidney disease (CKD) drugs market are F. Hoffmann-La Roche Ltd., Pfizer Inc., Sanofi S.A., GlaxoSmithKline Plc, Kissei Pharmaceutical Co. Ltd., and AbbVie Inc.

Global Chronic Kidney Disease (CKD) Drugs Market: Overview

This report on the global chronic kidney disease (CKD) drugs market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments. The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment for the period from 2014 to 2024, considering the macro and micro environmental factors. Growth rates for each segment within the global chronic kidney disease (CKD) drugs market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.

A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also provide insights into the key trends of the chronic kidney disease (CKD) drugs market such as novel treatment approaches such as monoclonal antibodies, RNA-based therapies and stem cell based therapies. The key market indicators influencing global Chronic Kidney Disease (CKD) Drugs market taken into consideration including cost constraints and regulatory landscape. The report also includes market attractiveness analysis of the major segments that provides a thorough analysis of the overall competitive scenario in the global Chronic Kidney Disease (CKD) Drugs market. The report also highlights key events of the global Chronic Kidney Disease (CKD) Drugs industry. A porter’s five force analysis highlighting competitive landscape is also included in the report.

Market revenue in terms of US$ Mn for the period between 2014 and 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all the segments, considering 2015 as the base year. The year on year growth of global Chronic Kidney Disease (CKD) Drugs market for each segment is also reflected. Additionally, market related factors such as increasing preference for product innovation, and cost reduction for hospitals and greater affordability for patients in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.

Global Chronic Kidney Disease (CKD) Drugs Market: Segmentation

Based on product type, the global Chronic Kidney Disease (CKD) Drugs market has been segmented into ACE Inhibitors, Angiotensin-II receptor blockers, Calcium channel blockers, Beta blockers, Erythropoiesis-stimulating agents (ESAs), Diuretics, and Others. Based on end-user, the market has been segmented into hospitals and specialty clinics. Hospitals segment is expected to remain dominant during the forecast period.

Geographically, the global Chronic Kidney Disease (CKD) Drugs market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the regions have been further segmented into major countries from each region. These include the U.S., Canada, the U.K., Germany, France, Italy, Spain, China, Australia, India, Japan, Brazil, and Mexico.

Global Chronic Kidney Disease (CKD) Drugs Market: Competitive Landscape

The report also profiles major players in the Chronic Kidney Disease (CKD) Drugs market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. A thorough market share analysis of major companies operating in the Chronic Kidney Disease (CKD) Drugs market is provided in the report. Key companies profiled in the report include Keryx Biopharmaceuticals, Inc., Kissei Pharmaceutical Co., Ltd, AbbVie, Inc., GlaxoSmithKline plc., Sanofi S.A. , F. Hoffmann-La Roche Ltd., Pfizer, Inc., AstraZeneca plc, Amgen Inc., and Teva Pharmaceutical Industries Ltd.

The global Chronic Kidney Disease (CKD) Drugs market has been segmented as follows:

By Drug class

  • ACE Inhibitors
  • Angiotensin-II receptor blockers
  • Calcium channel blockers
  • Beta blockers
  • Erythropoiesis-stimulating agents (ESAs)
  • Diuretics
  • Others

By End User

  • Hospitals
  • Specialty Clinics

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Australia
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Rest of Middle East & Africa

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Chronic Kidney Disease

Buy Now